Glucosylceramidase

Glucosylceramidase 詳細

英語名Glucosylceramidase市販薬剤の数0
治験薬の数1ターゲットの別称Glucosylceramidase
研究&開発段階Phase 1 Clinical
英語名Glucosylceramidase
ターゲットの別称Glucosylceramidase
市販薬剤の数0
治験薬の数1
研究&開発段階Phase 1 Clinical

Glucosylceramidase 製品リスト

  • 属性

    Protein (1)

  • 製品ライブラリ

    オンライン (1)

  • Human (1)

  • タグ

    His Tag (1)

  • マーカー

    Unconjugated (1)

製品番号発現システム製品説明タンパク質の構造純度特性
Human
HEK293
Human Glucosylceramidase Protein, His Tag
総数量1
  • 1

Glucosylceramidaseバックグランド

Glucosylceramidase that catalyzes, within the lysosomal compartment, the hydrolysis of glucosylceramide/GlcCer into free ceramide and glucose. Thereby, it plays a central role in the degradation of complex lipids and the turnover of cellular membranes. Through the production of ceramides,it participates in the PKC-activated salvage pathway of ceramide formation and plays a role in cholesterol metabolism. It may either catalyze the glucosylation of cholesterol, through a transglucosylation reaction that transfers glucose from glucosylceramide to cholesterol. Defects in Glucosylceramidase are the cause of Gaucher disease, also known as glucocerebrosidase deficiency. Gaucher disease is the most prevalent lysosomal storage disease, characterized by accumulation of glucosylceramide in the reticulo-endothelial system. Currently, enzyme replacement therapy is used to treat patients with the disease.

Glucosylceramidase分子の別称

Glucosylceramidase,GBA,Acid beta-glucosidase,Alglucerase,beta-glucocerebrosidase,D-glucosyl-N-acylsphingosine glucohydrolase,EC 3.2.1.45,GBA,GBA1,GC,GCB,GLUC,glucosidase, beta, acid,glucosidase, beta,acid (includes glucosylceramidase),Glucosylceramidase,I

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
VQ-101VQ-101Phase 1 ClinicalVanqua Bio IncParkinson Disease
詳細
  • 詳細
  • 製品リスト
  • 治験薬に関する情報
お問い合わせ

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8